5-iodo-2,7-dimethyl-benzo[d]isoxazol-3-one | 864756-00-3

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 5-iodo-2,7-dimethyl-benzo[d]isoxazol-3-one
• 英文别名: 5-iodo-2,7-dimethyl-1,2-benzoxazol-3-one
• CAS: 864756-00-3
• 化学式: C₉H₈INO₂
• 分子量: 289.073
• InChiKey: RLMWOFFDHXSJKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-iodo-2,7-dimethyl-benzo[d]isoxazol-3-one 、 methyl 2-methoxy-3-methyl-5-[4-(5-methyl-1,3,4-oxadiazol-2-yl)but-1-ynyl]benzoate 在 四(三苯基膦)钯 三正丁基氢锡 、 copper(l) iodide 、 cesium fluoride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 以76 mg的产率得到(Z)-5-[1-(2,7-dimethyl-3-oxo-2,3-dihydro-benzo[d]isoxazol-5-yl)-4-(5-methyl-[1,3,4]oxadiazol-2-yl)-but-1-enyl]-2-methoxy-3-methylbenzoic acid methyl ester
  参考文献：
  名称：

  具有增强的水解稳定性的烯基二芳基甲烷HIV-1非核苷逆转录酶抑制剂的合成和生物学评估。

  摘要：

  HIV逆转录酶（NNRTIs）的非核苷抑制剂尽管不是HIV / AIDS治疗的主要手段，但由于其独特的作用机理，在高活性抗逆转录病毒疗法（HAART）中已变得越来越重要。几年前，我们的研究小组将烯基二芳基甲烷（ADAMs）鉴定为一种有效的新型NNRTIs。然而，发现活性最高的化合物在代谢上不稳定。随后的工作通过用各种杂环，腈和硫代酯代替不稳定的酯，从而合成了33种具有改善的代谢特性的类似物。结果，在纳摩尔浓度范围内鉴定出许多具有抗HIV活性的水解稳定的NNRTI。此外，基于新的ADAM系列，开发了一种改进的药效团模型，

  DOI：

  10.1021/jm070382k
• 作为产物：
  描述：

  2,N-dihydroxy-5-iodo-3-methylbenzamide 在 potassium carbonate 、 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 、 二甲基亚砜 为溶剂， 反应 26.0h， 生成 5-iodo-2,7-dimethyl-benzo[d]isoxazol-3-one
  参考文献：
  名称：

  Synthesis, Anti-HIV Activity, and Metabolic Stability of New Alkenyldiarylmethane HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors

  摘要：

  Non-nucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs) are part of the combination therapy currently used to treat HIV infection. Based on analogy with known HIV-1 NNRT inhibitors, 18 novel alkenyldiarylmethanes (ADAMs) containing 5-chloro-2-methoxyphenyl, 3-eyanophenyl, or 3-fluoro-5-trifluoromethylphenyl groups were synthesized and evaluated as HIV inhibitors. Their stabilities in rat plasma have also been investigated. Although introducing 5-chloro-2-methoxyphenyl or 3-fluoro-5-trifluoromethylphenyl groups into alkenyldiarylmethanes does not maintain the antiviral potency, the structural modification of alkenyldiarylmethanes with a 3-cyanophenyl substituent can be made without a large decrease in activity. The oxazolidinonyl group was introduced into the alkenyldiarylmethane framework and found to confer enhanced metabolic stability in rat plasma.

  DOI：

  10.1021/jm050452s

文献信息

• Alkenyldiarylmethanes, Fused Analogs And Syntheses Thereof
  申请人：Cushman Mark S.

  公开号：US20080300288A1

  公开（公告）日：2008-12-04

  Non-nucleoside inhibitors of HIV-1 reverse transcriptase are described. Such inhibitors may be used as part of a combination therapy to treat HIV infection. Compounds described herein exhibit antiviral potency. In addition, compounds described herein exhibit metabolic stability. Also described herein are processes for preparing Non-nucleoside inhibitors of HIV-1 reverse transcriptase.

  HIV-1反转录酶的非核苷类抑制剂被描述。这些抑制剂可以作为治疗HIV感染的联合疗法的一部分使用。本文描述的化合物具有抗病毒效力。此外，本文描述的化合物具有代谢稳定性。本文还描述了制备HIV-1反转录酶非核苷类抑制剂的过程。
• Synthesis and anti-HIV activity of new alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors (NNRTIs) incorporating benzoxazolone and benzisoxazole rings
  作者：Bo-Liang Deng、Matthew D. Cullen、Zhigang Zhou、Tracy L. Hartman、Robert W. Buckheit、Christophe Pannecouque、Erik De Clercq、Phillip E. Fanwick、Mark Cushman

  DOI：10.1016/j.bmc.2005.11.014

  日期：2006.4

  The HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) constitute a large and structurally diverse set of compounds, several of which are currently used in the treatment of AIDS. A series of novel alkenyldiarylmethanes (ADAMs) were designed and synthesized as part of an ongoing investigation to replace the metabolically labile methyl ester moieties found in the ADAM pharmacophore with stable modifications that retain the potent anti-HIV activity of the parent compounds. Unsurprisingly, the rat plasma half-lives of the new ADAMs were not improved when compared to the parent compounds, but all of the synthesized ADAMs inhibited the cytopathic effect of HIV-1 in cell culture. The most potent compound identified was (E)-5-[1-(3,7-dimethyl-2oxo-2,3-dihydro-benzoxazol-5-yl)-5-methoxycarbonyl-pent-1-enyl]-2-methoxy-3-methylbenzoic acid methyl ester (7), which inhibited the cytopathic effects of both HIV-1(RF) and HIV-1(IIIB) strains in cell cultures with EC50 values of 30 and 90 nM, respectively, and inhibited HIV-1 reverse transcriptase with an IC50 of 20 nM. (c) 2005 Elsevier Ltd. All rights reserved.
• Inhibition of tubulin polymerization by select alkenyldiarylmethanes
  作者：Matthew D. Cullen、Taradas Sarkar、Ernest Hamel、Tracy L. Hartman、Karen M. Watson、Robert W. Buckheit、Christophe Pannecouque、Erik De Clercq、Mark Cushman

  DOI：10.1016/j.bmcl.2007.11.114

  日期：2008.1

  During studies on the alkenyldiarylmethane (ADAM) class of non-nucleoside reverse transcriptase inhibitors (NNRTIs), analogues were discovered that exhibit low micromolar and submicromolar cytotoxicities. Since the ADAMs are structurally related to the tubulin polymerization inhibitor CC-5079, a set of 14 ADAMs were tested for inhibition of tubulin polymerization in an attempt to identify the biological target responsible for their cytotoxicity. The results indicate that, overall, the ADAMs are poor inhibitors of tubulin polymerization. However, the two most cytotoxic compounds, 15 and 16, are in fact active as inhibitors of tubulin assembly with IC50 values of 3.7 +/- 0.3 and 2.8 +/- 0.2 mu M, respectively, and they both inhibit the binding of colchicine to tubulin. Both compounds were investigated for anticancer activity in the National Cancer Institute's panel of 60 human cancer cell lines, and both compounds consistently displayed submicromolar cytotoxicities with mean-graph midpoint (MGM) values of 0.31 +/- 0.08 and 0.47 +/- 0.09 mu M, respectively. (c) 2007 Elsevier Ltd. All rights reserved.
• Replacement of the Metabolically Labile Methyl Esters in the Alkenyldiarylmethane Series of Non-Nucleoside Reverse Transcriptase Inhibitors with Isoxazolone, Isoxazole, Oxazolone, or Cyano Substituents
  作者：Bo-Liang Deng、Tracy L. Hartman、Robert W. Buckheit,、Christophe Pannecouque、Erik De Clercq、Mark Cushman

  DOI：10.1021/jm060449o

  日期：2006.8.1

  The alkenyldiarylmethanes (ADAMs) are a unique class of non-nucleoside reverse transcriptase inhibitors that have potential value in the treatment of HIV/AIDS. However, the potential usefulness of the ADAMs is limited by the presence of metabolically labile methyl ester moieties. A series of novel ADAMs were therefore designed and synthesized in order to replace the metabolically labile methyl ester moieties of the existing ADAM lead compounds with hydrolytically stable, fused isoxazolone, isoxazole, oxazolone, or cyano substituents on the aromatic rings. The methyl ester and methoxy substituents on both of the aromatic rings in the parent compound 1 were successfully replaced with metabolically stable moieties with retention of anti-HIV activity and a general decrease in cytotoxicity.
• [EN] ALKENYLDIARYLMETHANES, FUSED ANALOGS AND SYNTHESES THEREOF<br/>[FR] ALCENYLDIARYLMETHANES, ANALOGUES FONDUS ET SYNTHESE
  申请人：PURDUE RESEARCH FOUNDATION

  公开号：WO2007005531A2

  公开（公告）日：2007-01-11

  [EN] Non-nucleoside inhibitors of HIV-I reverse transcriptase are described. Such inhibitors may be used as part of a combination therapy to treat HIV infection. Compounds described herein exhibit antiviral potency. In addition, compounds described herein exhibit metabolic stability. Also described herein are processes for preparing Non-nucleoside inhibitors of HIV-I reverse transcriptase.
  [FR] L'invention concerne des inhibiteurs non nucléosidiques de la transcriptase inverse du VIH-I. Ces inhibiteurs peuvent être partiellement impliqués dans une polythérapie visant à traiter l'infection à VIH. Les composés de l'invention possèdent en outre un effet antiviral puissant, et se caractérisent par une stabilité métabolique. Par ailleurs, l'invention concerne des procédés de préparation de ces inhibiteurs non nucléosidiques de la transcriptase inverse du VIH-I.